清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

医学 全直肠系膜切除术 放化疗 结直肠癌 放射治疗 外科 阶段(地层学) 临床终点 化疗 内科学 随机对照试验 癌症 古生物学 生物
作者
Renu R. Bahadoer,Esmée A. Dijkstra,Boudewijn van Etten,Corrie A.M. Marijnen,Hein Putter,Elma Meershoek‐Klein Kranenbarg,Annet G.H. Roodvoets,Irıs D. Nagtegaal,Regina G. H. Beets‐Tan,Lennart K. Blomqvist,Tone Fokstuen,Albert J. ten Tije,Jaume Capdevila,Mathijs P. Hendriks,Ibrahim Edhemović,Andrès M.R. Cervantes,Per Johan Nilsson,Bengt L. G. Glimelius,Cornelis J.�H. van de Velde,Geke A.P. Hospers
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (1): 29-42 被引量:1807
标识
DOI:10.1016/s1470-2045(20)30555-6
摘要

Background Systemic relapses remain a major problem in locally advanced rectal cancer.Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial aimed to reduce distant metastases without compromising locoregional control.Methods In this multicentre, open-label, randomised, controlled, phase 3 trial, participants were recruited from 54 centres in the Netherlands, Sweden, Spain, Slovenia, Denmark, Norway, and the USA.Patients were eligible if they were aged 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, had a biopsy-proven, newly diagnosed, primary, locally advanced rectal adeno carcinoma, which was classified as high risk on pelvic MRI (with at least one of the following criteria: clinical tumour [cT] stage cT4a or cT4b, extramural vascular invasion, clinical nodal [cN] stage cN2, involved mesorectal fascia, or enlarged lateral lymph nodes), were mentally and physically fit for chemotherapy, and could be assessed for staging within 5 weeks before randomisation.Eligible participants were randomly assigned (1:1), using a management system with a randomly varying block design (each block size randomly chosen to contain two to four allocations), stratified by centre, ECOG performance status, cT stage, and cN stage, to either the experimental or standard of care group.All investigators remained masked for the primary endpoint until a prespecified number of events was reached.Patients allocated to the experimental treatment group received short-course radiotherapy (5 × 5 Gy over a maximum of 8 days) followed by six cycles of CAPOX chemotherapy (capecitabine 1000 mg/m² orally twice daily on days 1-14, oxaliplatin 130 mg/m² intravenously on day 1, and a chemotherapy-free interval between days 15-21) or nine cycles of FOLFOX4 (oxaliplatin 85 mg/m² intravenously on day 1, leucovorin [ folinic acid] 200 mg/m² intravenously on days 1 and 2, followed by bolus fluorouracil 400 mg/m² intravenously and fluorouracil 600 mg/m² intravenously for 22 h on days 1 and 2, and a chemotherapy-free interval between days 3-14) followed by total mesorectal excision.Choice of CAPOX or FOLFOX4 was per physician discretion or hospital policy.Patients allocated to the standard of care group received 28 daily fractions of 1•8 Gy up to 50•4 Gy or 25 fractions of 2•0 Gy up to 50•0 Gy (per physician discretion or hospital policy), with concomitant twice-daily oral capecitabine 825 mg/m² followed by total mesorectal excision and, if stipulated by hospital policy, adjuvant chemotherapy with eight cycles of CAPOX or 12 cycles of FOLFOX4.The primary endpoint was 3-year disease-related treatment failure, defined as the first occurrence of locoregional failure, distant metastasis, new primary colorectal tumour, or treatment-related death, assessed in the intention-to-treat population.Safety was assessed by intention to treat.This study is registered with the EudraCT, 2010-023957-12, and ClinicalTrials.gov,NCT01558921, and is now complete.Findings Between June 21, 2011, and June 2, 2016, 920 patients were enrolled and randomly assigned to a treatment, of whom 912 were eligible (462 in the experimental group; 450 in the standard of care group).Median follow-up was 4•6 years (IQR 3•5-5•5).At 3 years after randomisation, the cumulative probability of disease-related treatment failure was 23•7% (95% CI 19•8-27•6) in the experimental group versus 30•4% (26•1-34•6) in the standard of care group (hazard ratio 0•75, 95% CI 0•60-0•95; p=0•019).The most common grade 3 or higher adverse event during preoperative therapy in both groups was diarrhoea (81 [18%] of 460 patients in the experimental group and 41 [9%] of 441 in the standard of care group) and neurological toxicity during adjuvant chemotherapy in the standard of care group (16 [9%] of 187 patients).Serious adverse events occurred in 177 (38%) of 460 participants in the experimental group and, in the standard of care group, in 87 (34%) of 254 patients without adjuvant chemotherapy and in 64 (34%) of 187 with adjuvant chemotherapy.Treatment-related deaths occurred in four participants in the experimental group (one cardiac arrest, one pulmonary embolism, two infectious complications) and in four participants in the standard of care group (one pulmonary embolism, one neutropenic sepsis, one aspiration, one suicide due to severe depression).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
纯情的阁发布了新的文献求助10
5秒前
aspect完成签到 ,获得积分10
14秒前
bkagyin的应助被xun采纳,获得10
15秒前
优秀笑槐完成签到,获得积分10
18秒前
怕黑的又槐完成签到,获得积分10
19秒前
随心所欲完成签到 ,获得积分0
27秒前
酷炫安雁完成签到,获得积分10
29秒前
37秒前
纯情的阁完成签到,获得积分20
39秒前
xun发布了新的文献求助10
43秒前
53秒前
曾经的问夏完成签到 ,获得积分10
57秒前
怕黑的驳完成签到,获得积分10
57秒前
科研通AI6.4的应助被纯情的阁采纳,获得10
59秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
59秒前
热心的以松完成签到,获得积分10
1分钟前
体贴的电灯胆完成签到 ,获得积分10
1分钟前
悲凉的雁芙完成签到,获得积分10
1分钟前
自觉的三娘完成签到,获得积分10
1分钟前
潇洒的老黑完成签到,获得积分10
1分钟前
风趣香岚完成签到,获得积分10
1分钟前
jscshoping完成签到 ,获得积分10
1分钟前
迷路牛青完成签到,获得积分10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
阳光手机完成签到,获得积分10
2分钟前
重要静柏完成签到,获得积分10
2分钟前
2分钟前
大个的应助被wangruida采纳,获得10
2分钟前
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
2分钟前
2分钟前
纯情的阁发布了新的文献求助10
2分钟前
玩命的怀绿完成签到,获得积分10
2分钟前
纯情的阁发布了新的文献求助10
2分钟前
纯情的阁发布了新的文献求助10
2分钟前
wangruida完成签到,获得积分10
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158935
求助须知:如何正确求助?哪些是违规求助? 9554522
关于积分的说明 21719383
捐赠科研通 7748459
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370